Omeros (OMER) Starts Planned Pharmacokinetic Substudy In OMS302 Phase 3 Program
- 9:45 AM — May 31 —
- Source: iStockAnalyst
(By Balaseshan) Omeros Corp. (NASDAQ: OMER ), a clinical-stage biopharmaceutical company, said it has started the planned pharmacokinetic substudy in its Phase 3 clinical program evaluating OMS302 in patients undergoing intraocular lens replacement (ILR) surgery. Read More
Advertisement
Om
Biography
The sparingly named Om reunites the oft-heralded Sleep rhythm section of Al Cisneros (bass, vocals) and Chris Haikus (drums);... Read the full Om bio.
Om
Exclusives
Om
On Sale
Hot Music News
Adam Levine Romancing New Model
Catwalk Queen Caught Kissing Rocker
Jessica's Shocking Sex Confession
Jessica Simpson's Bedroom Tell-All
Life After Living in the Kardashian Shadow
Singer Fights to Shake the Kardashian Curse
Infertility Struggles Revealed
Joe Nichols Opens Up About Baby Drama